摘要
目的探讨CD8、CD68、FoxP3、程序性死亡因子1(PD1)和程序性死亡配体1(PD-L1)在子宫内膜癌组织中的表达及临床意义。方法收集2015年1月至2018年12月该院96例子宫内膜癌患者、68例子宫内膜组织正常女性为研究对象,采用免疫组化染色法检测肿瘤浸润性淋巴细胞(TILs)上标记抗体PD1、PD-L1、CD8、CD68、FoxP3表达,分析各指标表达差异及其与临床病理特征的关系。结果子宫内膜癌组织中CD8、CD68、FoxP3阳性率明显低于正常子宫内膜组织中阳性率,而子宫内膜癌组织TILs上PD1、PD-L1阳性率高于正常子宫内膜组织TILs中阳性率,差异有统计学意义(P<0.05)。CD8、CD68、FoxP3、PD1、PD-L1在病理学分级G3、有淋巴结转移子宫内膜癌组织中的阳性率高于在病理学分级G1~G2、无淋巴结转移子宫内膜癌组织中的阳性率,差异有统计学意义(P<0.05)。结论CD8、CD68、FoxP3、PD1、PD-L1异常上调参与子宫内膜癌前病变病情恶性进展,可对其进行监测,作为早期筛查子宫内膜癌前病变恶性转化生物标志物和治疗靶点。
Objective To investigate the expression and clinical significance of CD8,CD68,FoxP3,programmed death factor 1(PD1)and programmed death ligand 1(PD-L1)in endometrial cancer tissues.Methods A total of 96 endometrial cancer patients and 68 women with normal endometrial tissues in Guangyuan Central Hospital from January 2015 to December 2018 were collected.Immunohistochemical staining was used to determine the expression of the labeled antibodies PD1,PD-L1,CD8,CD68 and FoxP3 on tumor infiltrating lymphocytes(TILs).The expression difference of each index and their correlations with clinicopathological characteristics were analyzed.Results The positive expression rates of CD8,CD68 and FoxP3 in endometrial cancer tissues were lower than those in normal endometrial tissues,while the positive expression rates of PD1 and PD-L1 in TILs of endometrial cancer tissues were higher than those in TILs of normal endometrial tissues(P<0.05).The positive expression rates of CD8,CD68,FoxP3,PD1 and PD-L1 in endometrial cancer tissues at pathological grade G3 and with lymph node metastasis were higher than those at pathological grade G1-G2 and with non-lymph node metastasis(P<0.05).Conclusion CD8,CD68,FoxP3,PD1 and PD-L1 abnormally up-regulate and involve in the malignant progression of endometrial precancerous lesions,which could be monitored as early screening biomarkers and treatment targets for malignant transformation of endometrial precancerous lesions.
作者
李海军
边沁
何先伟
LI Haijun;BIAN Qin;HE Xianwei(Department of Clinical Laboratory,Guangyuan Central Hospital,Guangyuan,Sichuan 628000,China)
出处
《国际检验医学杂志》
CAS
2021年第10期1254-1258,共5页
International Journal of Laboratory Medicine
